Shenzhen Celconta Life Science Co., Ltd.
Shenzhen Celconta Life Science Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-07-01 | NCT07043907 | |
| PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors | Solid Tumors, Adult | Recruiting | Phase 1 | 2025-03-26 | NCT06897228 | |
| Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T) | Claudin18.2 Positive Advanced Solid Tumors | Recruiting | Phase 1 | 2025-01-17 | NCT06782425 |